MedTrace Logo

Satralizumab in Aneurysmal Subarachnoid Hemorrhage

NCT05727657 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2025-03-04

No results posted yet for this study

Summary

In this study, satralizumab will be administered to see whether satralizumab is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.

Conditions

  • Aneurysmal Subarachnoid Hemorrhage
  • Delayed Cerebral Ischemia

Interventions

DRUG

Satralizumab

120mg subcutaneous Day 0 and Day 14

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • University of Florida

    lead OTHER

Principal Investigators

  • Brian Hoh, MD · University of Florida

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2024-06-24
Completion
2024-06-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05727657 on ClinicalTrials.gov